Design Therapeutics, Inc. (DSGN): Capital Expenditures
$193.0K
Year ended 2025-12-31
$55.0K
Trailing 12 months to 2026-06-30
-40.5%
3-year compound annual growth
+20.5%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $193.0K | -43.2% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $340.0K | +32.8% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $256.0K | -72.1% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $918.0K | -40.3% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $1.54M | n/m | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $76.0K | n/a | 2022-03-10, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | 2025-12-31 | $193.0K | -43.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.84B | +55.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
Compare DSGN, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗